文献速递眼底病与葡萄膜炎青光眼神经眼科

表观遗传重编程用于眼部衰老与疾病:机制、生物标志物及临床转化之路

Epigenetic reprogramming for ocular aging and disease: Mechanisms, biomarkers, and the road to the clinic.
PubMed 文献 · Prog Retin Eye Res · 2026-01-21

综述指出,视网膜神经细胞长寿、分裂后且再生能力极低,使其易受年龄相关累积损伤。表观遗传改变(如异常DNA甲基化和组蛋白修饰)不仅是衰老相关现象,更是衰老与疾病(如青光眼和AMD)的根本驱动因素。表观遗传重编程通过短暂表达Yamanaka因子或化学混合物重置失调的表观遗传景观,临床前研究已在视神经病变模型中证实可恢复视力。

要点

  • 表观遗传改变是眼部衰老和不可逆致盲疾病(如青光眼、AMD)的根本驱动因素。
  • 表观遗传标记可逆,为治疗提供了不同于基因突变的新范式。
  • 临床前研究显示表观遗传重编程可在视神经病变模型中恢复视力。

核心结论

  • 表观遗传改变是眼部衰老及青光眼、AMD等不可逆致盲疾病的关键驱动因素,而非仅相关现象。
  • 表观遗传重编程(短暂表达Yamanaka因子或化学混合物)可重置失调的表观遗传景观,恢复细胞年轻状态。
  • 临床前研究已在视神经病变模型中验证该策略可恢复视力。

研究设计与样本

  • 综述文章,系统总结眼部衰老的表观遗传视角、重编程策略的前景与潜在问题及未来 rejuvenation 疗法。

主要发现

  • 视网膜神经细胞长寿、分裂后且再生能力极低,易受年龄相关累积损伤。
  • 异常DNA甲基化和组蛋白修饰破坏维持细胞身份与功能所需的稳定基因表达程序。
  • 表观遗传标记的可逆性为治疗提供了新范式。
  • 临床前研究显示重编程可 rejuvenate 受损和衰老神经元,在视神经病变模型中恢复视力。

临床怎么用

  • 表观遗传重编程有望成为眼科 rejuvenation 疗法的新方向,但需进一步临床转化研究。

局限性

  • 综述未报告具体临床试验数据,重编程策略的安全性和有效性仍需验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The eye's visual function relies on retinal neural cells that are long-lived, post-mitotic, and possess minimal regenerative capacity. These combined properties render them exceptionally vulnerable to the cumulative damage that drives age-related functional decline. Accumulating evidence now implicates epigenetic alterations, such as aberrant DNA methylation and histone modifications, not merely as correlates of aging but as fundamental drivers of aging and disease. These changes disrupt the stable gene expression programs required to maintain cellular identity and function, thereby contributing to the pathogenesis of irreversible blinding diseases like glaucoma and age-related macular degeneration (AMD). Unlike immutable genetic mutations, the reversible nature of these epigenetic marks offers a novel therapeutic paradigm. Epigenetic reprogramming, a strategy involving the transient expression of Yamanaka factors or chemical cocktails, provides a powerful means to reset this dysregulated epigenetic landscape and restore cells to a more youthful state. Compelling preclinical studies have validated this approach by demonstrating vision restoration in models of optic neuropathy through the rejuvenation of damaged and aged neurons. This review provides a comprehensive overview of ocular aging from an epigenetic perspective, examines the promise and potential concerns of epigenetic reprogramming, and discusses the future of rejuvenation therapies in ophthalmology.

来源:Prog Retin Eye Res,查看原文。版权归原作者所有。

引用

  1. Lee J, Han M, Wang K, et al. Epigenetic reprogramming for ocular aging and disease: Mechanisms, biomarkers, and the road to the clinic. Prog Retin Eye Res. 2026. PMID: 41577329. doi:10.1016/j.preteyeres.2026.101442

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。